Market Overview

Morgan Stanley Maintains on Allscripts Healthcare Solutions

Share:
Related MDRX
Jefferies: 10 Buyout Targets To Own During The M&A Boom
Stifel Sees 'Limited Growth Opportunities' For Allscripts

In a report published Wednesday, Morgan Stanley analyst Julie Murphy maintained an Overweight rating on Allscripts Healthcare Solutions (NASDAQ: MDRX), raising its price target to $20.00 from $17.00.

According to the report, following the previous Morgan Stanley note “What a Difference a Year Makes! Turnaround Thesis Validated” published this morning, analysts are updating model estimates and price target for MDRX.

“Our PT is based on a 2.7x EV/Sales multiple, the 2-yr avg FY1 multiple for MDRX pre-April 2012 (prior to the strategic alternatives upheaval seen that year) applied to our base case 2015 revenue est of $1,523M,” the report noted. “Our bull case valuation of $23 reflects a 2.9x EV/Sales multiple (3-yr avg multiple pre-April 2012) applied to our bull case 2015 revenue estimate of $1607M. Our bear case valuation of $14 is based on a 2.0x multiple (3-yr avg multiple) applied to our bear case 2015 revenue estimate of $1,471M.”

MDRX closed Tuesday at $15.52 with shares trading up at 2.51 percent.

Latest Ratings for MDRX

DateFirmActionFromTo
Apr 2015Stifel NicolausInitiates Coverage onHold
Mar 2015RW BairdInitiates Coverage onOutperform
Feb 2015BarclaysMaintainsEqualweight

View More Analyst Ratings for MDRX
View the Latest Analyst Ratings

Posted-In: Julie Murphy Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MDRX)

Around the Web, We're Loving...